MAD-CoV 2

Modern approaches for developing antivirals against SARS-CoV 2

FACTS & FIGURES

Start Date
End Date
Call
IMI2 - Call 21
Grant agreement number
101005026

Type of Action: 
RIA (Research and Innovation Action)

Contributions
IMI Funding
3 749 669
EFPIA in kind
2 655 500
Total Cost
6 405 169

Summary

ACE2 (angiotensin converting enzyme 2) is a protein found on the surface of the cells of our lungs and other organs. The SARS-CoV-2 virus, which causes COVID-19, uses ACE2 to break into and infect our cells.

The aim of the MAD-CoV 2 project is to build on and use this knowledge to develop innovative treatments for COVID-19. It will do this via a number of approaches, including engineering human tissue to test new treatments in the lab; studying how to exploit the role of ACE2; and mapping in detail the factors that are critical for virus replication.

The team hopes to rapidly translate this knowledge into new, targeted drugs to fight COVID-19 as well as any future coronavirus outbreaks. The project has committed to making its data and unique tissue reagents available to the entire community for drug testing and development, supporting all other efforts.

Achievements & News

Participants Show participants on map

EFPIA companies
  • Apeiron Biologics AG, Wien, Austria
  • Jlp Health GMBH, Vienna, Austria
  • Stemcell Technologies Uk LTD, Cambridge, United Kingdom
  • Vironova AB, Stockholm, Sweden
Universities, research organisations, public bodies, non-profit groups
  • Fundacio Institut De Bioenginyeria De Catalunya, Barcelona, Spain
  • Justus-Liebig-Universitaet Giessen, Giessen, Germany
  • Statens Veterinaermedicinska Anstalt, Uppsala, Sweden
Small and medium-sized enterprises (SMEs) and mid-sized companies (<€500 m turnover)
  • Inserm Transfert SA, Paris, France
  • Institut Fuer Molekulare Biotechnologie GMBH, Wien, Austria
Project coordinator
Ali Mirazimi
Statens Veterinaermedicinska Anstalt